Resolve the structure
Retains relevant experimental conformations and tracks the provenance of every receptor state used in a campaign.
Precision Oncology
Making chemotherapy work again in colorectal cancer.
Evolvia BioPharma is developing first-in-class, isoform-selective PHD1 (EGLN2) inhibitors that resensitize microsatellite-stable colorectal cancer to standard-of-care chemotherapy.
EBP-4 inhibits PHD1 to block adaptive resistance — keeping tumor cells sensitive, so chemotherapy drives apoptosis.
Evolvia AI Platform
Structure-first discovery for difficult drug targets.
Evolvia AI is the computational engine behind our discovery programs. It coordinates protein structures, metal chemistry, docking, and compound prioritization so scientists can understand not only which molecules rank highly, but whether the underlying binding model is chemically credible.
8biologically relevant metals
3integrated docking engines
166automated software tests
Respect metal chemistry
Applies metal-specific coordination rules for Zn, Fe, Mg, Mn, Cu, Ca, Co, and Ni instead of treating every catalytic center alike.
Route and evaluate
Works above AutoDock Vina, GNINA, and AutoDock4Zn to route compounds and assess whether predicted poses are geometrically plausible.
Prioritize with evidence
Combines docking results, coordination checks, and structural traceability to support decisions about which compounds to test next.
Built for validation
Explore a collaboration
From computational prediction to prospective testing
Evolvia AI is operational and released under an MIT license. Its next milestone is controlled benchmarking and prospective biochemical validation against conventional screening workflows.
The problem we target
Microsatellite-stable (MSS) colorectal cancer is ~95% of cases, does not respond to immunotherapy, and depends on chemotherapy that tumors eventually resist. No approved agent restores that lost chemosensitivity.
Prime
Selective PHD1 inhibition primes a latent p53 death program inside resistant tumor cells.
Activate
Standard chemotherapy (oxaliplatin, SN-38) then activates that primed program — restoring tumor-cell death.
Spare
Isoform selectivity leaves PHD2/PHD3 untouched, avoiding the HIF-driven toxicity that limited every prior PHD drug.
Why isoform-selective PHD1
Every clinical HIF-prolyl-hydroxylase inhibitor to date is pan-PHD and was developed for anemia — carrying HIF-driven cardiovascular and thrombotic liabilities. Evolvia engineers selectivity for PHD1, the isoform tied to the p53/NF-κB apoptotic axis, outside the conserved catalytic core.